In particular, the BRAF and MEK inhibitors currently in use, such as dabrafenib, vemurafenib and trametinib, showed encouraging response rates but their efficacy is limited by mechanisms of intrinsic or acquired resistance, frequently occurring in melanoma [5]. The gene discussed is BRAF; the disease is melanoma.